GlassScriptPhysician profile
Redempta Bekah
NPI 1518550680
$6,023.39
in general payments reported to CMS, 2019-2025
18 companies · $1,976 in 2025
The $1,976 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $787 · 2022: $383 · 2023: $1,528 · 2024: $1,350 · 2025: $1,976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,854.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,853.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,528.83 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $1,323.75 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Abbvie INC. | $557.19 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $532.06 | 2023-2025 | Cobenfy, Camzyos |
| Axsome Therapeutics, INC. | $357.31 | 2023-2025 | Auvelity |
| Novo Nordisk INC | $234.94 | 2021-2025 | Ozempic |
| Otsuka America Pharmaceutical, INC. | $209.40 | 2024-2025 | Rexulti |
| Amgen INC. | $208.90 | 2025 | Tezspire, Evenity |
| Astrazeneca Pharmaceuticals LP | $125.02 | 2023 | Fasenra |
| Braeburn INC. | $125.00 | 2025 | Brixadi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $116.97 | 2024 | |
| Tris Pharma INC | $114.14 | 2022 | |
| Sanofi-Aventis U.S. LLC | $113.34 | 2021 | |
| Edwards Lifesciences Corporation | $108.01 | 2025 | Sapien 3 Ultra Resilia |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $91.04 | 2025 | Rexulti |
| Esperion Therapeutics, INC. | $79.20 | 2021 | |
| Alkermes, INC. | $73.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Redempta Bekah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.